Union Korea Pharm Co., Ltd. (080720.KQ) Stock
Union Korea Pharm Co., Ltd.

Company profile
Union Korea Pharm reported revenue of 36.38 billion KRW for fiscal year 2025. South Korea was its largest region in fiscal year 2024, with 94% of revenue. Our analysis of its filings shows revenue shrinking from 63.17 billion KRW in fiscal year 2023 to 36.38 billion KRW in fiscal year 2025, 24.1% a year on average. Union Korea Pharm reports about 120 full-time employees.
What stands out
- It reported a net loss in each of its last 5 fiscal years; the loss widened from 20.87 billion KRW in fiscal year 2024 to 30.82 billion KRW in fiscal year 2025.
- Revenue fell 29.1% in fiscal year 2025, from 51.28 billion KRW in fiscal year 2024, after a fall of 18.8% the year before.
- Its net profit margin over the last four reported quarters was -95.5%, against a median of 5.5% for 6 listed companies of similar size in its industry.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Union Korea Pharm Co., Ltd.
Union Korea Pharm Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in South Korea. It offers pharmaceuticals in various formulations, including tablets, capsules, and injections. The company was formerly known as Union Pharmaceutical Co., Ltd. and changed its name to Union Korea Pharm Co., Ltd. in May 2001. Union Korea Pharm Co., Ltd. was founded in 1956 and is headquartered in Seongnam-si, South Korea.
Largest shareholders
- Melvin F&B Co. Ltd.19.92%
- Union Korea Pharm Co., Ltd.8.64%
- Sung-hee Shin5.163 %5.16%
- So-ryung Kim2.022 %2.02%
- Seung-gyu Baek0.6319 %0.63%
Share of the company, as of September 25, 2026
Leadership
- Keunho Chung — CEO & Representative Director, 65
- SooGeun Lim — President & Internal Director, 47
- SeungHee Lim — MD & Executive Director, 59
How much revenue does Union Korea Pharm make?
Union Korea Pharm reported 36.38 billion KRW in revenue for fiscal year 2025, down 29.1% from 51.28 billion KRW in fiscal year 2024.
Where does Union Korea Pharm make most of its revenue?
South Korea: 94% of revenue by region in fiscal year 2024, followed by Overseas (6%).
What companies are similar to Union Korea Pharm?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include JW Holdings Corporation (096760.KS), Samjin Pharmaceuticals Co., Ltd. (005500.KS), Korea United Pharm Inc. (033270.KS), Hyundai Pharmaceutical Co., Ltd. (004310.KS).
Has Union Korea Pharm made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 11.11 billion KRW; FY2022, a loss of 932.02 million KRW; FY2023, a loss of 18.16 billion KRW; FY2024, a loss of 20.87 billion KRW; FY2025, a loss of 30.82 billion KRW. It reported a net loss in each of these 5 years.
How has Union Korea Pharm's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 48.30 billion KRW; FY2022, 61.29 billion KRW; FY2023, 63.17 billion KRW; FY2024, 51.28 billion KRW; FY2025, 36.38 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Union Korea Pharm Co., Ltd. (080720.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/080720.KQ